At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
In Brief
A Phase 3 clinical trial evaluating CNTO 1959 50 mg, CTNO 1959 100 mg, and 2 other interventions for Psoriasis. Completed, enrolled 192 participants across 27 sites.
Detailed Summary
The purpose of this study is to demonstrate the superiority of CNTO 1959 (guselkumab) to placebo in the treatment of participants with moderate to severe plaque-type psoriasis (A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches).
Study Details
Timeline
Interventions
Participants will receive subcutaneous injection of CNTO 1959 50 mg.
Participants will receive subcutaneous injection of CNTO 1959 100 mg.
Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.
Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.